Sobi finalized the acquisition of EmaCo AG, including Emapalumab and related assets, on 18 July 2019.
For more information on Sobi, please visit www.sobi.com
Novimmune SA will continue to operate and focus on its bispecific technology and associated programs and will rebrand under “Light Chain Bioscience – A brand of Novimmune SA”.
For more information, please visit www.lightchainbio.com
TM & Copyright ©2019 EmaCo AG. All rights reserved.